Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 88c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 88c

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

February 24, 2022 4:05 PM EST

Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to date

$917.2 million of sotrovimab collaboration revenue recognized in 2021

Multiple commercial and clinical value drivers expected across the portfolio in 2022

SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021.

2021 was a transformative year in which we delivered our first blockbuster medicine,... More